Patient-tailored immunotherapies
Source Nature Biomedical Engineering
Engineered T Cells May Be Harnessed to Kill Solid Tumor Cells
Novel immunotherapy extends therapy now used in fighting leukemia, Tel Aviv University researchers say There is now a multitude of therapies to treat cancer, from chemotherapy and radiation to immunotherapy and small molecule inhibitors. Chemotherapy is still the most widely used cancer treatment, but chemotherapy attacks all the rapidly dividing cells that it locates within
‘Express courier service’ for immune cells
Immunotherapy is a promising cancer treatment that uses genetically modified immune cells to fight cancer. It can be used as a primary treatment or in combination with other treatments such as radiation and chemotherapy to slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body.
Duvelisib Gains FDA Orphan Drug Designation for T-Cell Lymphomas
The FDA has granted duvelisib (Copiktra) with an orphan drug designation for the treatment of patients with T-cell lymphoma, according to a press release from Verastem Oncology, the company developing duvelisib.1 The PI3K-δ,γ inhibitor demonstrated efficacy in a phase I study and is currently being investigated in the phase II PRIMO trial (NCT03372057). “Receiving orphan
Drugs in the Pipeline: Non-Small-Cell Lung Cancer
Source Cancer Network Several promising drugs for the treatment of lung cancer have been garnering attention over recent years. These new treatments have been highlighted at conferences and are sure to impact the standard of care. Some of these new treatments are detailed below. LOXO-292 Various multikinase inhibitors (MKI) with some activity against RET have
Multiple myeloma treatment granted FDA Orphan Drug Designation
Orphan Drug Designation has been given to bispecific antibody candidate, GBR 1342, for the treatment of multiple myeloma. The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Glenmark Pharmaceuticals’ bispecific antibody candidate GBR 1342 for the treatment of patients with multiple myeloma who have received prior therapies. “Patients who are struggling with diseases like
Research Continues to Drive Advances Against Cancer following AACR Cancer Progress Report 2019
AACR Cancer Progress Report 2019 details 27 new cancer treatments, a record high number of U.S. cancer survivors, and the benefit of increasing federal investments in medical research through the National Institutes of Health and the National Cancer Institute The American Association for Cancer Research (AACR) today released its annual Cancer Progress Report highlighting how research largely
Novartis’ Phase III studies of ofatumumab achieve primary goals in relapsing multiple sclerosis
Novartis has reported positive findings from the Phase III ASCLEPIOS I and II clinical trials of ofatumumab (OMB157), which met their primary endpoints in relapsing forms of multiple sclerosis (RMS) patients. Ofatumumab is an anti-CD20 monoclonal antibody (mAb) designed to cause B-cell lysis and depletion. It has been formulated for once-monthly, subcutaneous self-administration. The identical
Fedratinib Approval Further Validates JAK Inhibition for Myelofibrosis Treatment
Source Targeted Oncology JAK inhibition continues to drive progress in myelofibrosis treatment as fedratinib (Inrebic) now joins ruxolitinib (Jakafi) in the treatment landscape for myelofibrosis. Since its FDA approval in August 2019, fedratinib has become both an additional treatment and a second-line option for patients who respond poorly to ruxolitinib. The approval of fedratinib was
Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer
Source https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(19)30339-X?elqTrackId=39785ec7f12f4ed79ff115249bc871f5&elq=81c0af21c850457daca48d5be457f158&elqaid=26028&elqat=1&elqCampaignId=10599 Invariant natural killer T (iNKT) cells are potent immune cells for targeting cancer; however, their clinical application has been hindered by their low numbers in cancer patients. Here, we developed a proof-of-concept for hematopoietic stem cell-engineered iNKT (HSC-iNKT) cell therapy with the potential to provide therapeutic levels of iNKT cells for a patient’s